South African startup Immobazyme said it raised $1.45 million in venture funding, bringing total funding to $2.9 million, as part of a push to expand local biomanufacturing capacity. The company focuses on precision fermentation and advanced biomanufacturing aimed at producing affordable recombinant proteins, enzymes, and growth factors. The report connects the funding to broader concerns about the continent’s dependence on imported biologics and the regulatory lag that can constrain biosimilars and newer platform modalities. The article points to regulatory modernization needs and highlights manufacturing capacity gaps, including the limited presence of GMP biosimilar manufacturers. For industry watchers, the Immobazyme update is a concrete example of capital targeting capacity-building efforts in a region where supply-chain resilience is increasingly treated as a strategic health security issue.